Yue Cui

发表

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

W. Wilson, A. LaCasce, M. Czuczman, 2010, The Lancet. Oncology.

Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis

I. Nestorov, Yue Cui, A. Deykin, 2017, Journal of clinical pharmacology.

Safety, Pharmacokinetics, Pharmacodynamics, and Activity of Navitoclax, a Targeted High Affinity Inhibitor of BCL-2, in Lymphoid Malignancies

W. Wilson, M. Czuczman, J. Leonard, 2011 .

Th1/Th2 cytokine profiles and their relationship to clinical features in patients following nonmyeloablative allogeneic stem cell transplantation

Hongwei Wang, Yue Cui, Lei Zhu, 2004, American journal of hematology.

The optimal timing of radiotherapy in the combination treatment of limited-stage extranodal natural killer/T-cell lymphoma, nasal type: an updated meta-analysis

Yue Cui, Yongsheng Jiang, Yu-yi Yao, 2021, Annals of Hematology.

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

D. Arnold, G. Nelles, M. Kremenchutzky, 2018, Therapeutic advances in neurological disorders.

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Hao Xiong, Yue Cui, T. Kipps, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial

R. Bermel, B. Kieseier, S. Newsome, 2016, Therapeutic advances in neurological disorders.

Long-Term Safety and Efficacy of CT-Guided I125 Radioactive Seed Implantation as a Salvage Therapy for Recurrent Head and Neck Squamous Carcinoma: A Multicenter Retrospective Study

Yue Cui, Junjie Wang, Haitao Sun, 2021, Frontiers in Oncology.

Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study

P. Calabresi, K. Selmaj, Yue Cui, 2014, Expert opinion on drug delivery.

A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy

Meiqing Feng, Yue Cui, Lei Tang, 2021, The Journal of biological chemistry.

Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study

I. Nestorov, Yue Cui, A. Deykin, 2015, British journal of clinical pharmacology.

An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations

Daniel J Sargent, Sumithra J Mandrekar, Yue Cui, 2007, Statistics in medicine.

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jeffrey A Jones, T. Kipps, L. Swinnen, 2010 .

An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

A. Roberts, W. Wierda, S. Enschede, 2008 .

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial

R. Bermel, B. Kieseier, S. Newsome, 2016, Therapeutic advances in neurological disorders.